Hester Biosciences Ltd (HESTERBIO) Q3FY26 Concall Summary - Dec-2025 Qtr
Performance Overview
- The company reported a phase of improved execution and capacity strengthening, particularly in the Poultry Healthcare business, which saw robust growth.
- Overall standalone revenue grew by 12% in Q3, with a significant 140% year-on-year increase in Profit After Tax (PAT), driven by a favorable product mix and sustained cost discipline.
- The Animal Healthcare division faced a significant decline due to timing-related delays in government-led immunization programs, which are expected to resume in Q4 FY26.
- A key milestone was achieved post-quarter end with the receipt of manufacturing and marketing licenses for the H9N2 Avian Influenza vaccine, strengthening the company's poultry vaccine portfolio for both domestic and export markets.
- The company successfully capitalized its fill/finish facility during the quarter, effectively doubling its drug product capacity to support future growth across products and markets.
Financial Metrics
Log in to Stocksigma to read the Financial Metrics section of this summary.
Operating Performance / Business Segments
Log in to Stocksigma to read the Operating Performance / Business Segments section of this summary.
Key Discussions & Insights
Log in to Stocksigma to read the Key Discussions & Insights section of this summary.
Outlook and Guidance
Log in to Stocksigma to read the Outlook and Guidance section of this summary.
Challenges / Concerns
Log in to Stocksigma to read the Challenges / Concerns section of this summary.
Industry / Competitive Landscape
Log in to Stocksigma to read the Industry / Competitive Landscape section of this summary.
Overall Summary
Log in to Stocksigma to read the Overall Summary section of this summary.